Moderna Stock Analysis

MRNA -  USA Stock  

USD 132.06  5.56  4.04%

The current indifference towards the small price fluctuations of Moderna may encourage investors to take a closer look at the firm as it is trading at a share price of 132.06 on 6,124,550 in trading volume. The company management teams did not add any value to Moderna investors in April. However, most investors can still diversify their portfolios with Moderna to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.07. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Moderna partners.
Additionally, see Stocks Correlation.
The Moderna stock analysis report makes it easy to digest most publicly released information about Moderna and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Moderna Stock analysis module also helps to analyze the Moderna price relationship with some important fundamental indicators such as market cap and management efficiency.

Moderna Stock Analysis Notes

About 64.0% of the company shares are owned by institutional investors. The company recorded earning per share (EPS) of 16.69. Moderna had not issued any dividends in recent years. The entity had 1:10 split on the 3rd of August 2017. Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Moderna operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2700 people. To find out more about Moderna contact Michael French at 617 714 6500 or learn more at

Moderna Quarterly Cost of Revenue

1.02 Billion


Moderna Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Moderna's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Moderna or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Moderna has very high historical volatility over the last 90 days
Moderna has a strong financial position based on the latest SEC filings
About 64.0% of the company shares are owned by institutional investors
Latest headline from Vaccine Stocks Pfizer, BioNTech Score A Win Leading Pfizer To Make A Bullish Move - Investors Business Daily

Moderna Upcoming and Recent Events

Earnings reports are used by Moderna to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Moderna previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Moderna Largest EPS Surprises

Earnings surprises can significantly impact Moderna's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Moderna SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Moderna prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Moderna investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Moderna specific information freely available to individual and institutional investors to make a timely investment decision.
13th of May 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
11th of May 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
4th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
3rd of May 2022
Submission of Matters to a Vote of Security Holders
11th of April 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
24th of February 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
14th of February 2022
Unclassified Corporate Event
10th of February 2022
Unclassified Corporate Event

Moderna Thematic Classifications

In addition to having Moderna stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Biotech IdeaBiotech
Biotechnology and pharmaceuticals production and services

Moderna Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Moderna is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Moderna backward and forwards among themselves. Moderna's institutional investor refers to the entity that pools money to purchase Moderna's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Baillie Gifford CoCommon Shares45.6 M7.9 B
Blackrock IncCommon Shares28.7 M4.9 B
Vanguard Group IncCommon Shares27 M4.7 B
Flagship Pioneering IncCommon Shares17.6 MB
State Street CorpCommon Shares14.8 M2.6 B
Coatue Management LlcCommon Shares6.9 M1.2 B
Geode Capital Management LlcCommon Shares6.4 M1.1 B
Susquehanna International Group LlpCall Options4.2 M716.5 M
Susquehanna International Group LlpPut Options3.9 M669.8 M
Note, although Moderna's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Moderna Market Capitalization

The company currently falls under 'Large-Cap' category with current market capitalization of 55.24 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Moderna's market, we take the total number of its shares issued and multiply it by Moderna's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Moderna Profitablity

Moderna's profitability indicators refer to fundamental financial ratios that showcase Moderna's ability to generate income relative to its revenue or operating costs. If, let's say, Moderna is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Moderna's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Moderna's profitability requires more research than a typical breakdown of Moderna's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 66.06 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 71.98 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.72.
Last ReportedProjected for 2022
Return on Average Assets 0.66  0.71 
Return on Average Equity 1.40  1.51 
Return on Invested Capital 3.25  3.51 
Return on Sales 0.72  0.77 

Management Efficiency

The entity has return on total asset (ROA) of 51.93 % which means that it generated profit of $51.93 on every $100 spent on asset. This is very large. Similarly, it shows return on stockholders equity (ROE) of 146.08 %, meaning that it created $146.08 on every $100 dollars invested by stockholders. Moderna management efficiency ratios could be used to measure how well moderna manages its routine affairs as well as how well it operates its assets and liabilities. The current year Return on Average Assets is expected to grow to 0.71. The current year Return on Average Equity is expected to grow to 1.51. Moderna Total Assets are projected to increase significantly based on the last few years of reporting. The past year's Total Assets were at 24.67 Billion. The current year Current Assets is expected to grow to about 17.3 B, whereas Tax Assets are forecasted to decline to about 291.7 M.
Last ReportedProjected for 2022
Book Value per Share 35.10  37.87 
Enterprise Value over EBIT 7.00  7.55 
Enterprise Value over EBITDA 7.23  7.80 
Price to Book Value 7.28  8.49 
Tangible Assets Book Value per Share 61.21  66.04 
Enterprise Value97.8 B105.5 B
Tangible Asset Value24.7 B26.6 B

Technical Drivers

As of the 24th of May, Moderna secures the Downside Deviation of 4.03, mean deviation of 3.94, and Risk Adjusted Performance of 0.015. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Moderna, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for Moderna, which can be compared to its peers in the industry. Please verify Moderna coefficient of variation, maximum drawdown, skewness, as well as the relationship between the information ratio and downside variance to decide if Moderna is priced some-what accurately, providing market reflects its recent price of 132.06 per share. Given that Moderna has jensen alpha of 0.2236, we recommend you to check Moderna's last-minute market performance to make sure the company can sustain itself at a future point.

Moderna Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Kaufman Adaptive Moving Average allows the user to define Moderna range across which they want the smoothing.

Moderna Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Moderna insiders, such as employees or executives, is commonly permitted as long as it does not rely on Moderna's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Moderna insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Moderna Predictive Daily Indicators

Moderna intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Moderna stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Moderna Forecast Models

Moderna time-series forecasting models is one of many Moderna's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Moderna's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Moderna Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Moderna stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Moderna shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Moderna. By using and applying Moderna Stock analysis, traders can create a robust methodology for identifying Moderna entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin 0.73  0.79 
Gross Margin 0.86  0.86 
Profit Margin 0.66  0.71 
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Moderna operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2700 people.

Current Moderna Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Moderna analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Moderna analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Moderna current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Moderna analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Moderna stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Moderna, talking to its executives and customers, or listening to Moderna conference calls.
Moderna Analyst Advice Details

Moderna Stock Analysis Indicators

Moderna stock analysis indicators help investors evaluate how Moderna stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Moderna shares will generate the highest return on investment. By understating and applying Moderna stock analysis, traders can identify Moderna position entry and exit signals to maximize returns.
Quick Ratio1.54
Fifty Two Week Low119.01
Revenue Growth1,162.90%
Shares Short Prior Month16.21M
Average Daily Volume Last 10 Day6.79M
Average Daily Volume In Three Month7.17M
Shares Percent Shares Out3.88%
Gross Margins75.05%
Short Percent Of Float5.20%
Forward Price Earnings15.72
Float Shares365.3M
Fifty Two Week High497.49
Enterprise Value To Ebitda3.28
Fifty Day Average154.28
Two Hundred Day Average251.87
Enterprise Value To Revenue2.40
Additionally, see Stocks Correlation. Note that the Moderna information on this page should be used as a complementary analysis to other Moderna's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Complementary Tools for Moderna Stock analysis

When running Moderna price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
CEO Directory
Screen CEOs from public companies around the world
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Is Moderna's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine Moderna value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.